Combined hormone replacement therapy use in relation to breast cancer mortality.

越来越明显的是，接受联合激素替代疗法（CHRT）的女性患乳腺癌的风险增加，然而，这种形式的激素使用对乳腺癌死亡率的潜在影响尚未得到彻底的研究，目前我们对这种影响的了解（如果有的话）是不完整的。我们建议通过连接几个省级数据文件，包括人口登记、生命统计登记、萨斯喀彻温省癌症登记、处方药计划、医院服务、医生服务和乳腺癌筛查计划，对加拿大萨斯喀彻温省1990年至2007年乳腺癌死亡进行一项基于人群的巢式病例对照研究。在萨斯喀彻温省卫生部（一个公共资助的卫生保健系统）注册的每个人都有一个唯一的卫生服务编号，使个人的记录能够在这些数据文件之间链接起来。这些数据的可用性将允许相对有效地评估乳腺癌死亡风险与CHRT使用的持续时间、近期和类型有关，包括总体和特定组织学类型（导管和小叶）的乳腺癌。

DESCRIPTION (provided by applicant): Project Summary It has become increasingly evident that women who are taking combined hormone replacement therapy (CHRT) are at an increased risk of developing breast cancer, however, the potential impact of this form of hormone use on breast cancer mortality has not been thoroughly studied, and, at present our knowledge of this impact (if any) is incomplete. We propose to conduct a population-based nested case-control study of breast cancer deaths from 1990 through 2007 in Saskatchewan, Canada by linking several provincial-level data files, including the population registry, vital statistics registry, Saskatchewan Cancer Registry, Prescription Drug Plan, hospital services, physician services, and the Breast Cancer Screening Program. Each person registered with Saskatchewan Health (a publicly funded health care system) has a unique Health Services Number which enables an individual's records to be linked across these data files. The availability of these data will permit a relatively efficient assessment of the risk of breast cancer death in relation to the duration, recency, and type of CHRT use, both overall and for specific histologic types (ductal and lobular) of breast cancer. PUBLIC HEALTH RELEVANCE: Relevance In recent years epidemiologic studies are reasonably clear in their findings of an increased breast cancer incidence in postmenopausal women who have taken combined hormone replacement therapy (CHRT). However, what is not clear is the degree to which the increase in incidence will translate into an increase in breast cancer mortality - only a single study has compared mortality rates from breast cancer among women without breast cancer who do and do not initiate CHRT - and the results from this study were inconclusive. Because CHRT continues to be widely used (some two million American women are receiving this treatment at the present time), and because CHRT has benefits that have to be weighted against the risks, an assessment of breast cancer mortality in CHRT users represents an important undertaking.